Thus, our study opens this field to explore other new therapeutic agents targeted on PGC1α and PGC1β pathways for protection against not only alcoholic liver diseases but also metabolic syndrome and obesity, the major world-wide health problems, especially when superimposed in alcohol abusers. The gene discussed is PPARGC1B; the disease is obesity due to melanocortin 4 receptor deficiency.